Needham Reiterates Buy on Boston Scientific, Maintains $97 Price Target

Needham analyst Mike Matson has reiterated a Buy rating on Boston Scientific (NYSE: BSX) and has maintained a price target of $97 for the stock. This endorsement suggests confidence in the company's performance and potential for growth.